Characterization of the C-MYC-regulated Transcriptome by SAGE: Identification and Analysis of C-MYC Target Genes
Overview
Authors
Affiliations
To identify target genes of the oncogenic transcription factor c-MYC, serial analysis of gene expression (SAGE) was performed after adenoviral expression of c-MYC in primary human umbilical vein endothelial cells: 216 different SAGE tags, corresponding to unique mRNAs, were induced, whereas 260 tags were repressed after c-MYC expression (P < 0.05). The induction of 53 genes was confirmed by using microarray analysis and quantitative real-time PCR: among these genes was MetAP2/p67, which encodes an activator of translational initiation and represents a validated target for inhibition of neovascularization. Furthermore, c-MYC induced the cell cycle regulatory genes CDC2-L1, Cyclin E binding protein 1, and Cyclin B1. The DNA repair genes BRCA1, MSH2, and APEX were induced by c-MYC, suggesting that c-MYC couples DNA replication to processes preserving the integrity of the genome. MNT, a MAX-binding antagonist of c-MYC function, was up-regulated, implying a negative feedback loop. In vivo promoter occupancy by c-MYC was detected by chromatin immunoprecipitation for CDK4, Prohibitin, MNT, Cyclin B1, and Cyclin E binding protein 1, showing that these genes are direct c-MYC targets. The c-MYC-regulated genes/tags identified here will help to define the set of bona fide c-MYC targets and may have potential therapeutic value for inhibition of cancer cell proliferation, tumor-vascularization, and restenosis.
Shen Y, Yao Y, Li H, Li Y, Hu Y BMC Infect Dis. 2025; 25(1):326.
PMID: 40055592 PMC: 11887161. DOI: 10.1186/s12879-025-10726-8.
An oncoprotein CREPT functions as a co-factor in MYC-driven transformation and tumor growth.
Li M, Li J, He C, Jiang G, Ma D, Guan H J Biol Chem. 2024; 301(1):108030.
PMID: 39615685 PMC: 11730240. DOI: 10.1016/j.jbc.2024.108030.
Li Y, Min X, Zhang X, Cao X, Kong Q, Mao Q Cell Mol Life Sci. 2024; 81(1):404.
PMID: 39277835 PMC: 11402889. DOI: 10.1007/s00018-024-05427-5.
Immune evasion: An imperative and consequence of MYC deregulation.
Krenz B, Lee J, Kannan T, Eilers M Mol Oncol. 2024; 18(10):2338-2355.
PMID: 38957016 PMC: 11459038. DOI: 10.1002/1878-0261.13695.
Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer.
Hamilton G, Stickler S, Rath B Curr Cancer Drug Targets. 2024; 24(9):930-940.
PMID: 38275056 DOI: 10.2174/0115680096272757231211113206.